Drug Trial Radar · NCT06162169
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Nov 25, 2023
Primary completion
Feb 20, 2024
Study completion Feb 20, 2024
Sponsor
- Lead sponsor
- Allist Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole, rifampicin, and omeprazole in healthy subjects.
Conditions
- Healthy Subjects
Interventions
JAB-21822Drug
JAB-21822 was administered orally
ItraconazoleDrug
Itraconazole was administered orally
OmeprazoleDrug
Omeprazole was administered orally
Midazolam , Rosuvastatin calcium and digoxinDrug
Midazolam , Rosuvastatin calcium and digoxin was administered orally
RifampicinDrug
Rifampicin was administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observed maximum concentrations (Cmax )of JAB-21822Time frame: approximately 10 days
- Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of JAB-21822Time frame: approximately 10 days
- Area under the concentration versus time curve from dose to infinity (AUC0-∞) of JAB-21822Time frame: approximately 10 days
- Observed maximum concentrations (Cmax )of midazolam, rosuvastatin, and digoxinTime frame: approximately 10 days
- Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of midazolam, rosuvastatin, and digoxinTime frame: approximately 10 days
- Area under the concentration versus time curve from dose to infinity (AUC0-∞) of midazolam, rosuvastatin, and digoxinTime frame: approximately 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.